公开(公告)号：US20230330229A1

公开(公告)日：2023-10-19

申请号：US17998708

申请日：2021-05-11

申请人： UNIVERSITE CLAUDE BERNARD LYON 1 ,  NH THERAGUIX ,  CENTRE GEORGES FRANCOIS LECLERC ,  The Brigham and Women's Hospital, Inc.

发明人： François LUX ,  Olivier TILLEMENT ,  Géraldine LE DUC ,  Aurélien MEYZAUD ,  Magali ROUFFIAC ,  Céline MIRJOLET ,  Daniel CAGNEY ,  Ross BERBECO ,  Needa Virani

IPC分类号： A61K41/00 ,  A61K49/18 ,  A61P35/04 ,  A61N5/10

CPC分类号： A61K41/0038 ,  A61K49/1881 ,  A61P35/04 ,  A61N5/1049 ,  A61N5/1067 ,  A61N2005/1055 ,  A61N2005/1098

摘要： The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by magnetic resonance image-guided radiation therapy in a subject in need thereof, said method comprising the steps of:



(i) administering an efficient amount of high-Z element containing nanoparticles having, contrast enhancement for magnetic resonance imaging and/or radiosensitizing properties for radiation therapy, in a subject in need thereof, and,
(ii) exposing said subject to magnetic resonance image-guided radiation therapy by means of a Magnetic Resonance Imaging Guided Linear Accelerator (MR-Linac),

wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40, preferably higher than 50, and said nanoparticles have a mean hydrodynamic diameter below 20 nm, for example between 1 and 10 nm, preferably between 2 and 8 nm.

公开(公告)号：US20180236108A1

公开(公告)日：2018-08-23

申请号：US15831661

申请日：2017-12-05

申请人： Jacobson Research Laboratory Limited

发明人： Connie Sau-Kuen Kwok ,  Kwok Kin Cheng

IPC分类号： A61K49/18

CPC分类号： A61K49/1854 ,  A61K49/186 ,  A61K49/1881

摘要： The present invention relates to a composition for use as a contrast agent in medical imaging. The composition comprises a metal ion containing compound comprises at least one metal ion adapted to bind with one or more metal ion chelating agents; wherein said one or more metal ion chelating agents comprise at least one first chelating agent adapted to target a region of interest being imaged, and at least one second chelating agent having at least one functional group adapted to dissociate in an aqueous medium to thereby allow or enhance contrast of the region of interest under the medical imaging. The present invention further relates to a diagnostic agent for use in amyloid (Aβ) protein detection under magnetic resonance imaging (MRI) comprising the above described composition; and a method of preparing thereof.

公开(公告)号：US20180008730A1

公开(公告)日：2018-01-11

申请号：US15706429

申请日：2017-09-15

申请人： William Marsh Rice University

发明人： Nancy J. Halas ,  Ciceron Ayala-Orozco ,  Sandra Bishnoi ,  Luke Henderson ,  Oara Neumann ,  Robia Pautler

IPC分类号： A61K49/18 ,  C23C18/16 ,  C23C18/31 ,  H01B3/02

CPC分类号： A61K49/1881 ,  A61K49/1833 ,  C23C18/1646 ,  C23C18/31 ,  H01B3/02

摘要： A Magnetic Resonance Imaging (MRI) enhancement agent includes a plurality of particles, each particle including: a metal core; a dielectric shell disposed on the metal core comprising at least one MRI contrast agent; and a metal shell disposed on the exterior surface of the dielectric shell that encapsulates the dielectric shell.

公开(公告)号：US20150132384A1

公开(公告)日：2015-05-14

申请号：US14382495

申请日：2013-03-04

申请人： The Governing Council of the University of Toronto

发明人： Xiao Yu Wu ,  Alireza Shalviri ,  Ping Cai

IPC分类号： C08F251/00 ,  A61K9/14 ,  A61K31/197 ,  A61K47/36 ,  A61K38/08 ,  A61K31/704 ,  A61K47/32

CPC分类号： C08F251/00 ,  A61K9/14 ,  A61K9/5161 ,  A61K9/5192 ,  A61K31/197 ,  A61K31/704 ,  A61K38/08 ,  A61K47/32 ,  A61K47/36 ,  A61K49/0093 ,  A61K49/1818 ,  A61K49/1881 ,  B82Y40/00 ,  C08F8/00 ,  C08J3/14 ,  C08F222/1006 ,  C08F220/34 ,  C08F220/06 ,  C08F2220/286 ,  C08F2220/1891

摘要： Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.

摘要翻译： 描述了用于控制药物递送的淀粉基pH响应纳米颗粒的合成和表征。 通过新的一锅法合成了具有各种摩尔比的淀粉与MAA的聚甲基丙烯酸接枝淀粉（PMAA-g-St）纳米粒子，其能够在水性介质中同时接枝PMAA和纳米颗粒形成。 NMR数据显示聚山梨醇酯80聚合成接枝聚合物。 纳米颗粒相对球形，具有窄尺寸分布和多孔表面形态，并在生理pH范围内显示pH依赖性溶胀。 体积相变的粒度和大小取决于PMAA含量和制剂参数，如表面活性剂水平，交联剂量和总单体浓度。 结果表明，新的pH响应纳米粒子具有控制药物递送的有用性质。

公开(公告)号：US20140303081A1

公开(公告)日：2014-10-09

申请号：US14240081

申请日：2012-08-31

申请人： Shanta Dhar ,  Sean Marrache

发明人： Shanta Dhar ,  Sean Marrache

IPC分类号： A61K38/17 ,  A61K45/06 ,  A61K47/48 ,  A61K31/315 ,  A61K38/08

CPC分类号： A61K38/1709 ,  A61K31/315 ,  A61K38/08 ,  A61K45/06 ,  A61K47/54 ,  A61K47/549 ,  A61K47/6921 ,  A61K47/6935 ,  A61K47/6937 ,  A61K49/0067 ,  A61K49/0093 ,  A61K49/1881

摘要： Nanoparticles include a core and one or more targeting moieties, as well as one or more contrast agents or one or more therapeutic agents. The contrast agents or therapeutic agents may be contained or embedded within the core. If the nanoparticle includes therapeutic agents, the agents are preferably released from the core at a desired rate. The core may be biodegradable and may release the agents as the core is degraded or eroded. The targeting moieties preferably extend outwardly from the core so that they are available for interaction with cellular components, which interactions will target the nanoparticles to the appropriate cells, such as apoptotic cells; organelles, such as mitochondria; or the like. The targeting moieties may be tethered to the core or components that interact with the core.

摘要翻译： 纳米颗粒包括核心和一个或多个靶向部分，以及一种或多种造影剂或一种或多种治疗剂。 造影剂或治疗剂可以包含或嵌入核心内。 如果纳米颗粒包括治疗剂，则试剂优选以所需的速率从芯中释放。 核心可以是可生物降解的，并且当核心被降解或侵蚀时可释放药剂。 靶向部分优选从核心向外延伸，使得它们可用于与细胞组分相互作用，所述相互作用将靶向纳米颗粒到合适的细胞，例如凋亡细胞; 细胞器，如线粒体; 或类似物。 靶向部分可以连接到与核相互作用的核心或组分。

公开(公告)号：US08617522B2

公开(公告)日：2013-12-31

申请号：US13729815

申请日：2012-12-28

申请人： University of Florida Research Foundation, Inc.

发明人： Parvesh Sharma ,  Brij M. Moudgil ,  Glenn A. Walter ,  Stephen R. Grobmyer ,  Swadeshmukul Santra ,  Huabei Jiang ,  Scott Chang Brown ,  Edward W. Scott ,  Qizhi Zhang ,  Niclas Bengtsson

IPC分类号： A61K49/04 ,  A61K49/00 ,  A61B5/055 ,  A61N5/00

CPC分类号： A61K49/222 ,  A61B5/0035 ,  A61B5/0059 ,  A61B5/0095 ,  A61B5/055 ,  A61B6/00 ,  A61K41/0052 ,  A61K49/0002 ,  A61K49/0093 ,  A61K49/0423 ,  A61K49/1806 ,  A61K49/1881 ,  A61M31/005 ,  A61N5/10 ,  B82Y5/00

摘要： Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more of luminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic purposes such as ablation of tumors or by neutron capture in addition to use as contrast agents for imaging.

摘要翻译： 多峰纳米颗粒是含有PAT造影剂和发光成像，X射线成像和/或MRI中的一种或多种的纳米颗粒。 多峰纳米颗粒可以具有包含在芯上具有金属涂层的氧化物的介电芯。 颗粒可以是金属斑点。 多模式纳米颗粒可用于治疗目的，例如肿瘤的消融或中子捕获以及用作成像的造影剂。

公开(公告)号：US20080286370A1

公开(公告)日：2008-11-20

申请号：US12093187

申请日：2006-10-17

申请人： Armin Kuebelbeck ,  Heike Schilke

发明人： Armin Kuebelbeck ,  Heike Schilke

IPC分类号： A61K9/16 ,  A61K38/43 ,  A61K38/16 ,  A61K39/395 ,  A61K49/18

CPC分类号： A61K49/1881 ,  B82Y5/00

摘要： The invention relates to nanoscale particles as contrast agents for magnetic resonance imaging, consisting of a core having an inert matrix, one or more covalently bonded organic complexing agents in which one or more metal ions having unpaired electrons are bonded, and optionally one or more biomolecules covalently bonded to the surface of the cores, and to a process for the production of these nanoparticles.

摘要翻译： 本发明涉及作为磁共振成像造影剂的纳米尺寸颗粒，其由具有惰性基质的芯，一种或多种共价键合的有机络合剂组成，其中一个或多个具有不成对电子的金属离子键合，以及任选的一种或多种生物分子 共价结合到芯的表面，以及制备这些纳米颗粒的方法。

公开(公告)号：US07235227B2

公开(公告)日：2007-06-26

申请号：US10400379

申请日：2003-03-26

申请人： Gregory M. Lanza ,  Samuel A. Wickline

发明人： Gregory M. Lanza ,  Samuel A. Wickline

IPC分类号： A61B5/055

CPC分类号： B82Y5/00 ,  A61K49/1881

摘要： An improved contrast agent for magnetic resonance imaging comprises particles to each of which is coupled a multiplicity of chelating agents containing paramagnetic ions. In the improved agent, the position of the ion is offset from the surface of the particle so as to improve the relaxivity imparted by the contrast agent. A tether offsetting the chelate from the surface of the particle may optionally contain cleavage sites permitting more facile excretion of the chelated paramagnetic ion.

摘要翻译： 用于磁共振成像的改进的造影剂包括颗粒，其中每个颗粒与多个含有顺磁离子的螯合剂偶联。 在改进剂中，离子的位置偏离颗粒的表面，从而提高造影剂赋予的松弛度。 螯合物从颗粒表面偏移的系链可以任选地含有允许螯合顺磁离子更容易排泄的切割位点。

公开(公告)号：US20060233712A1

公开(公告)日：2006-10-19

申请号：US10559957

申请日：2004-06-07

申请人： Soledad Penades ,  Manuel Martin-Lomas ,  Jesus Martines De La Fuente ,  Thomas Rademacher

发明人： Soledad Penades ,  Manuel Martin-Lomas ,  Jesus Martines De La Fuente ,  Thomas Rademacher

IPC分类号： A61K49/00 ,  A61K48/00 ,  A61K39/00 ,  A61K33/24

CPC分类号： A61K47/48923 ,  A61K9/5094 ,  A61K47/6923 ,  A61K47/6929 ,  A61K49/1845 ,  A61K49/1881 ,  B82Y5/00 ,  Y10T428/2991

摘要： Materials and methods for making small magnetic particles, e.g. clusters of metal atoms, which can be employed as a substrate for immobilising a plurality of ligands. Also disclosed are uses of these magnetic nanoparticles as therapeutic and diagnostic reagents, and in the study of ligand-mediated interactions.

摘要翻译： 用于制造小磁性颗粒的材料和方法，例如， 可以用作固定多个配体的底物的金属原子簇。 还公开了这些磁性纳米颗粒作为治疗和诊断试剂以及在配体介导的相互作用的研究中的用途。

公开(公告)号：US5468465A

公开(公告)日：1995-11-21

申请号：US271921

申请日：1994-07-06

申请人： Edward A. Deutsch ,  Karen F. Deutsch ,  William P. Cacheris ,  William H. Ralston ,  David H. White ,  Dennis L. Nosco ,  Robert G. Wolfangel ,  Janet B. Wilking ,  Linda Meeh ,  Steven R. Woulfe

发明人： Edward A. Deutsch ,  Karen F. Deutsch ,  William P. Cacheris ,  William H. Ralston ,  David H. White ,  Dennis L. Nosco ,  Robert G. Wolfangel ,  Janet B. Wilking ,  Linda Meeh ,  Steven R. Woulfe

IPC分类号： A61B5/055 ,  A61B19/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/04 ,  A61K49/18 ,  A61K49/22 ,  C01B25/32 ,  C01G28/00 ,  C01G31/00 ,  C01G45/00 ,  C07F9/38

CPC分类号： A61K49/225 ,  A61K47/48861 ,  A61K49/1818 ,  A61K49/183 ,  A61K49/1842 ,  A61K49/1881 ,  A61B2090/3925 ,  A61B2090/3954 ,  A61B90/39 ,  Y10S977/722 ,  Y10S977/775 ,  Y10S977/881 ,  Y10S977/91 ,  Y10S977/927 ,  Y10S977/928 ,  Y10S977/929 ,  Y10S977/93 ,  Y10T436/24

摘要： Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ("MRI"), magnetic resonance spectroscopy ("MRS"), magnetic resonance spectroscopy imaging (37 MRSI"), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the abovedescribed apatite particles and then performing the medical diagnostic procedure.

摘要翻译： 公开了治疗磷灰石颗粒，用于增强诸如磁共振成像（“MRI”），磁共振光谱学（“MRS”），磁共振光谱成像（37MRSI“），X射线诊断成像和超声成像的医学诊断成像。 公开了新颖的涂层和制造技术来控制颗粒尺寸和颗粒聚集，从而获得用于肝脏，脾脏，胃肠道或组织疾病状态的器官特异性成像的组合物。根据诊断成像技术，将磷灰石颗粒处理为 磷灰石颗粒也可以被氟化以形成用于19F成像的稳定的氟磷灰石组合物。还公开了执行医学诊断程序的诊断组合物和方法，其涉及向温血动物施用诊断有效量的 上述磷灰石颗粒，然后执行药物 诊断程序。